MedTrace Logo

An Extension Study to Further Evaluate the Safety, Tolerability of GBT440 in Patients With Sickle Cell Disease Who Participated in the Study GBT440-001

NCT03041909 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2019-01-02

Study results available
· View outcomes & findings →

Summary

This is an open label, single arm study which enrolled 5 subjects with SCD who previously participated in the GBT440-001 study (NCT02285088).

Conditions

Interventions

DRUG

GBT440

Oral drug

Sponsors & Collaborators

  • Global Blood Therapeutics

    lead INDUSTRY

Principal Investigators

  • Josh Lehrer-Graiwer, MD · Global Blood Therapeutics, Inc.

  • Timothy Mant, FRCP, FFPM · Quintiles, Inc.

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2017-06-30
Completion
2017-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03041909 on ClinicalTrials.gov